SSTR3

Chr 22

somatostatin receptor 3

Also known as: SS-3-R, SS3-R, SS3R, SSR-28, SST3

NCBI Gene: 6753ENSG00000278195UniProt: P32745

This gene encodes a member of the somatostatin receptor protein family. Somatostatins are peptide hormones that regulate diverse cellular functions such as neurotransmission, cell proliferation, and endocrine signaling as well as inhibiting the release of many hormones and other secretory proteins. Somatostatin has two active forms of 14 and 28 amino acids. The biological effects of somatostatins are mediated by a family of G-protein coupled somatostatin receptors that are expressed in a tissue-specific manner. Somatostatin receptors form homodimers and heterodimers with other members of the superfamily as well as with other G-protein coupled receptors and receptor tyrosine kinases. This protein is functionally coupled to adenylyl cyclase. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]

99
ClinVar variants
17
Pathogenic / LP
0.00
pLI score
1
Active trials
Clinical Summary— SSTR3
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
17 Pathogenic / Likely Pathogenic· 75 VUS of 99 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.42LOEUF
pLI 0.000
Z-score 0.67
OE 0.76 (0.43–1.42)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.14Z-score
OE missense 0.82 (0.73–0.91)
247 obs / 303.0 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.76 (0.43–1.42)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.82 (0.73–0.91)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.07
0≤1.21.6
LoF obs/exp: 7 / 9.2Missense obs/exp: 247 / 303.0Syn Z: -0.61

ClinVar Variant Classifications

99 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic16
Likely Pathogenic1
VUS75
Likely Benign5
Conflicting1
16
Pathogenic
1
Likely Pathogenic
75
VUS
5
Likely Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
16
0
16
Likely Pathogenic
0
0
1
0
1
VUS
0
71
4
0
75
Likely Benign
0
4
0
1
5
Benign
0
0
0
0
0
Conflicting
—1
Total07521198

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SSTR3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
HTR6 and SSTR3 ciliary targeting relies on both IC3 loops and C-terminal tails.
Barbeito P et al.·Life Sci Alliance
2020
Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas.
Lamszus K et al.·J Neurooncol
1997Review
Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S et al.·J Neurosurg
2023
Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.
Muscarella LA et al.·Cell Oncol (Dordr)
2011Cohort
Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential.
Behling F et al.·Neurosurg Rev
2022
Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review.
Wijaya RR et al.·Ann Nucl Med
2025Review
World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC.
Rogoll D et al.·Eur J Endocrinol
2025
The immunohistochemical expression of SSTR2A is an independent prognostic factor in meningioma.
Fodi C et al.·Neurosurg Rev
2022
Prognostic impact of somatostatin receptor expression in advanced bladder cancer.
Maas M et al.·Urol Oncol
2020
Somatostatin receptors and disease: role of receptor subtypes.
Hofland LJ et al.·Baillieres Clin Endocrinol Metab
1996Review
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Identification of the LncRNA PRNCR1/miR-642a-5p/SSTR3 CeRNA network and its diagnostic value in type 2 diabetes mellitus.
Chen J et al.·Diabetol Metab Syndr
2025🔓 Open Access
The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties against Pancreatic Neuroendocrine Tumors.
Bistika M et al.·Neuroendocrinology
2025
Selective ligand recognition and activation of somatostatin receptors SSTR1 and SSTR3.
Wang Y et al.·Proc Natl Acad Sci U S A
2024🔓 Open Access
CPEB2 inhibits preeclampsia progression by regulating SSTR3 translation through polyadenylation.
Zhao Y et al.·Biochim Biophys Acta Mol Basis Dis
2024
The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.
Di Muro G et al.·Int J Mol Sci
2024🔓 Open Access
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov
Desmoplastic Small Round Cell TumorSynovial Sarcoma

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

RECRUITING
NCT06456359Phase PHASE2University Hospital HeidelbergStarted 2024-12-19
Signifor

External Resources

Links to major genomics databases and tools